Journal of Applied Physiology, Vol 72, Issue 6 2415-2419, Copyright © 1992 by American Physiological Society

ARTICLES

A thromboxane mimetic, U-46619, produces plasma exudation in airways of the guinea pig

J. Lotvall, W. Elwood, K. Tokuyama, T. Sakamoto, P. J. Barnes and K. F. Chung
Department of Thoracic Medicine, Royal Brompton National Heart and Lung Hospital, London, United Kingdom.

Thromboxane A2 (TxA2) has been implicated in airway responses to allergen and in the bronchial hyperresponsiveness observed in asthma. Furthermore a TxA2 receptor antagonist and a TxA2 synthase inhibitor inhibit plasma exudation in airways induced by inhaled platelet-activating factor. To evaluate whether TxA2 has any direct effect on plasma exudation in the airways, we studied the effect of a stable TxA2 mimetic (U-46619; 2, 20, and 200 nmol/kg iv) on lung resistance (RL) and Evans blue dye extravasation (marker of plasma albumin; 20 mg/kg iv) at the airway levels of trachea, main bronchi, and proximal and distal intrapulmonary airways in anesthetized, tracheostomized, and mechanically ventilated guinea pigs. Injection of U-46619 produced an immediate and marked dose-dependent increase in RL, which peaked at approximately 30 s. At the highest dose of U-46619, we also observed a later increase in RL, starting at approximately 3 min and reaching a second peak at approximately 8 min. Mean systemic blood pressure increased in a dose-dependent manner [maximum 82 +/- 8 (SE) mmHg]. U-46619 also produces dose-dependent plasma exudation, measured as Evans blue dye extravasation, at all airway levels as well as into the tracheal lumen. Airway responses to U-46619 (200 nmol/kg iv) were abolished in animals pretreated with the TxA2 receptor antagonist ICI-192605 (0.5 mg/kg iv). We conclude that U-46619, despite being a vasoconstrictor, is potent in inducing plasma exudation in airways and that this effect is mediated via a TxA2 receptor.

This article has been cited by other articles:

				I. C. Allen, J. M. Hartney, T. M. Coffman, R. B. Penn, J. Wess, and B. H. Koller Thromboxane A2 induces airway constriction through an M3 muscarinic acetylcholine receptor-dependent mechanism Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L526 - L533. [Abstract] [Full Text] [PDF]

				S. Murakami, N. Nagaya, T. Itoh, M. Kataoka, T. Iwase, T. Horio, Y. Miyahara, Y. Sakai, K. Kangawa, and H. Kimura Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L59 - L65. [Abstract] [Full Text] [PDF]

				E. Bohm, G. J. Sturm, I. Weiglhofer, H. Sandig, M. Shichijo, A. McNamee, J. E. Pease, M. Kollroser, B. A. Peskar, and A. Heinemann 11-Dehydro-thromboxane B2, a Stable Thromboxane Metabolite, Is a Full Agonist of Chemoattractant Receptor-homologous Molecule Expressed on TH2 Cells (CRTH2) in Human Eosinophils and Basophils J. Biol. Chem., February 27, 2004; 279(9): 7663 - 7670. [Abstract] [Full Text] [PDF]

				J. Tamaoki, M. Kondo, J. Nakata, Y. Nagano, K. Isono, and A. Nagai Effect of a Thromboxane A2 Antagonist on Sputum Production and Its Physicochemical Properties in Patients With Mild to Moderate Asthma Chest, July 1, 2000; 118(1): 73 - 79. [Abstract] [Full Text] [PDF]

				T. Kriston, R. C. Venuto, C. Baylis, and G. Losonczy Hemodynamic and renal effects of U-46619, a TXA2/PGH2 analog, in late-pregnant rats Am J Physiol Regulatory Integrative Comp Physiol, March 1, 1999; 276(3): R831 - R837. [Abstract] [Full Text] [PDF]

				P. J. Barnes, K. F. Chung, and C. P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596. [Abstract] [Full Text] [PDF]

				M. Yamasaki, T. Matsumoto, S. Fukuda, T. Nakayama, H. Nagaya, and Y. Ashida Involvement of Thromboxane A2 and Histamine in Experimental Allergic Rhinitis of Guinea Pigs J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1471 - 1479. [Abstract] [Full Text]